Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs Medpace Holdings Inc — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $13.22, while Medpace Holdings Inc trades at $530 (market cap $15.08B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| KTEC | MEDP | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $19.51 | $620.59 |
52-Week Low | $12.00 | $308.88 |
Market Cap | — | $15.08B |
Enterprise Value | — | $14.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC stock trades at $13.28, up 2.23% today, but technical indicators show a bearish trend with moving averages and ADX signaling selling pressure. Key financial ratios are unavailable, limiting fundamental assessment. The stock lacks recent news coverage, and support and resistance levels are concentrated at $13, indicating a critical price zone.
The outlook is cautious due to weak technicals and missing fundamental data. Investment opportunities hinge on future earnings clarity, while risks include market volatility and potential downside if support at $13 fails. Investors need updated financials to gauge valuation and growth prospects accurately.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
